arrow
S

Sarah P. Hammond

massachusetts general hospital
H指数:34
被引数:4,295

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

B-Cell Depletion Relative to Tumor Necrosis Factor Inhibition Extends the Duration of Viral Shedding in COVID-19 Among Autoimmune Disease Patients: A Matched Prospective Cohort Study

在自身免疫病患者中,与肿瘤坏死因子抑制剂相比,B细胞耗竭延长了COVID-19的病毒脱落持续时间:一项匹配的前瞻性队列研究

2026-09-200
OAAI
An Open-Label Phase II Trial of Sotrovimab (VIR-7831) Prophylaxis Against COVID-19 Infection in Immunocompromised Individuals with Impaired SARS-CoV-2 Humoral Immunity

一项关于Sotrovimab(VIR-7831)预防COVID-19感染的开放标签II期临床试验,研究对象为SARS-CoV-2体液免疫受损的免疫抑制个体

2025-08-080
OAAI
Olorofim for the treatment of invasive fungal diseases in patients with few or no therapeutic options: a single-arm, open-label, phase 2b study

奥罗芬尼用于治疗无或有限治疗选择的侵袭性真菌病患者:一项单臂、开放标签、2b期研究

2025-06-180
PRE
Population-based longitudinal study over two decades of Candida and Candida-like species bloodstream infection reveals gender and species differences in mortality, recurrence and resistance

一项为期二十年的基于人群的纵向研究揭示了念珠菌及念珠菌样菌种血流感染在死亡率、复发和耐药性方面的性别与菌种差异。

2025-05-220
OA
Modeling suggests SARS-CoV-2 rebound after nirmatrelvir-ritonavir treatment is driven by target cell preservation coupled with incomplete viral clearance
2025-02-040
OAAI
Comparative Outcomes of Babesiosis in Immunocompromised and Nonimmunocompromised Hosts: A Multicenter Cohort Study
2025-01-280
PRE
Modeling Invasive Aspergillosis Risk for the Application of Prophylaxis Strategies

建立侵袭性曲霉病风险模型以应用预防策略

2024-02-067
OAAI
SARS-CoV-2 viral clearance and evolution varies by type and severity of immunodeficiency
2024-01-2427
OA